Interested in learning more about Ilyas's ILP-technology, local-acting immunotherapies or any of the trials SITU-SAFE, SITU-SURGERY, SITU-HEAL or SITU-GUT or our recent work in AMR and meet our CEO Evelina Vågesjö, please reach out.
The thesis will be defended in a hearing open to the public at the Swedish University of Agricultural Sciences on Tuesday 5th September (09:00-12:00) in Undervisningshuset Sal L, SLU, Uppsala.
For the third consecutive year Ilya Pharma is invited to share updates regarding its ILP100-Topical program to the US Military largest medical conference, Military Health Systems Research Symposium (MHSRS).
This week Professor Mia Phillipson is giving a presentation at the Broad Institute of MIT and Harvard in Boston about her research at Uppsala University in gut barrier, immune cell functions and how they can be targeted at the the Peyers Patches and giving an update on Ilya Pharmas ILP100-Oral program for patients experiencing ICI-induced colitis.
Data is presented by Andreas Fasth, Head of Clinical Development and Medical Affairs who will also participate in the two-day EWMA innovation forum with selected experts and stakeholders.